Nothing Special   »   [go: up one dir, main page]

MXPA05009135A - Formulaciones liquidas de las proteinas de union del factor necrosis del tumor. - Google Patents

Formulaciones liquidas de las proteinas de union del factor necrosis del tumor.

Info

Publication number
MXPA05009135A
MXPA05009135A MXPA05009135A MXPA05009135A MXPA05009135A MX PA05009135 A MXPA05009135 A MX PA05009135A MX PA05009135 A MXPA05009135 A MX PA05009135A MX PA05009135 A MXPA05009135 A MX PA05009135A MX PA05009135 A MXPA05009135 A MX PA05009135A
Authority
MX
Mexico
Prior art keywords
binding proteins
necrosis factor
tumor necrosis
liquid formulations
tnf
Prior art date
Application number
MXPA05009135A
Other languages
English (en)
Inventor
Fabrizio Samaritani
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of MXPA05009135A publication Critical patent/MXPA05009135A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invencion se refiere a una formulacion estable, farmaceuticamente aceptable, acuosa de la proteina de union TNF, que comprende una proteina de union TNF, un amortiguador y un agente de isotonicidad.
MXPA05009135A 2003-02-28 2004-02-11 Formulaciones liquidas de las proteinas de union del factor necrosis del tumor. MXPA05009135A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03100505 2003-02-28
PCT/EP2004/050118 WO2004075918A1 (en) 2003-02-28 2004-02-11 Liquid formulations of tumor necrosis factor-binding proteins

Publications (1)

Publication Number Publication Date
MXPA05009135A true MXPA05009135A (es) 2005-10-20

Family

ID=32921619

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009135A MXPA05009135A (es) 2003-02-28 2004-02-11 Formulaciones liquidas de las proteinas de union del factor necrosis del tumor.

Country Status (22)

Country Link
US (3) US8937045B2 (es)
EP (1) EP1603596B1 (es)
JP (1) JP4980048B2 (es)
KR (1) KR20050105486A (es)
CN (1) CN100563712C (es)
AR (1) AR043418A1 (es)
AT (1) ATE394123T1 (es)
BR (1) BRPI0407649A (es)
CA (1) CA2515539A1 (es)
DE (1) DE602004013557D1 (es)
EA (1) EA009079B1 (es)
ES (1) ES2304602T3 (es)
HK (1) HK1085677A1 (es)
HR (1) HRP20050706A2 (es)
IL (1) IL170414A (es)
MX (1) MXPA05009135A (es)
NO (1) NO20054440L (es)
PL (1) PL213501B1 (es)
RS (1) RS51041B (es)
UA (1) UA82503C2 (es)
WO (1) WO2004075918A1 (es)
ZA (1) ZA200506504B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
NZ602498A (en) * 2007-11-30 2014-08-29 Abbvie Inc Protein formulations and methods of making same
SG175188A1 (en) * 2009-05-04 2011-11-28 Abbott Biotech Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
PL2637690T3 (pl) 2010-11-11 2017-03-31 Abbvie Biotechnology Ltd Płynne formulacje zawierające przeciwciało anty-tnf alfa o wysokim stężeniu
WO2013006454A1 (en) 2011-07-01 2013-01-10 Biogen Idec Ma Inc. Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use
TWI595883B (zh) 2011-10-18 2017-08-21 柯赫勒斯生物科學有限公司 用木糖醇穩定化之依那西普調配物
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
JP6120452B2 (ja) 2011-10-31 2017-04-26 ジェネンテック， インコーポレイテッド 抗体製剤
BR112015000203A2 (pt) 2012-07-09 2017-06-27 Coherus Biosciences Inc formulações de etanercept que exibem redução marcada em partículas sub-visíveis
MX360044B (es) 2012-09-11 2018-10-19 Coherus Biosciences Inc Etanercept plegado correctamente con alta pureza y un rendimiento excelente.
JP6431844B2 (ja) 2012-10-26 2018-11-28 ルピン アトランティス ホールディングス エスエーＬｕｐｉｎ Ａｔｌａｎｔｉｓ Ｈｏｌｄｉｎｇｓ Ｓａ Ｔｎｆｒ：ｆｃ融合プロテインの安定な医薬組成物
JP5684954B1 (ja) 2014-06-26 2015-03-18 丸石製薬株式会社 安定性を改善したロクロニウム製剤
RU2724900C1 (ru) * 2019-10-24 2020-06-26 Маруиси Фармасьютикал Ко., Лтд. Препарат рокурония с улучшенной стабильностью

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
EP0839046B1 (en) * 1995-07-14 2002-01-23 Applied Research Systems ARS Holding N.V. Tnf receptor and steroid hormone dhea in a combined therapy
MA24169A1 (fr) * 1996-05-08 1997-12-31 Hoffmann La Roche Traitement de l'asthme a l'aide de la tnfr-ig
DK0942740T3 (da) * 1996-12-06 2003-12-15 Amgen Inc Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
US20030180287A1 (en) * 2002-02-27 2003-09-25 Immunex Corporation Polypeptide formulation

Also Published As

Publication number Publication date
CA2515539A1 (en) 2004-09-10
US20070053906A1 (en) 2007-03-08
ATE394123T1 (de) 2008-05-15
US20150098950A1 (en) 2015-04-09
EP1603596A1 (en) 2005-12-14
AU2004216483A1 (en) 2004-09-10
HK1085677A1 (en) 2006-09-01
EP1603596B1 (en) 2008-05-07
HRP20050706A2 (en) 2005-12-31
RS51041B (sr) 2010-10-31
AR043418A1 (es) 2005-07-27
ZA200506504B (en) 2006-12-27
UA82503C2 (uk) 2008-04-25
EA200501230A1 (ru) 2006-04-28
PL378290A1 (pl) 2006-03-20
IL170414A (en) 2009-11-18
KR20050105486A (ko) 2005-11-04
PL213501B1 (pl) 2013-03-29
WO2004075918A1 (en) 2004-09-10
JP2006519210A (ja) 2006-08-24
DE602004013557D1 (de) 2008-06-19
CN1774266A (zh) 2006-05-17
CN100563712C (zh) 2009-12-02
JP4980048B2 (ja) 2012-07-18
EA009079B1 (ru) 2007-10-26
ES2304602T3 (es) 2008-10-16
BRPI0407649A (pt) 2006-02-21
NO20054440L (no) 2005-09-26
US9512215B2 (en) 2016-12-06
RS20050662A (en) 2007-11-15
US8937045B2 (en) 2015-01-20
US20170020960A1 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
RS20050662A (en) Liquid formulations of tumor necrosis factor-binding proteins
MXPA05002814A (es) Formulacion para agentes lipofilicos.
MY142354A (en) Acidic insulin preparations having improved stability
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
BR0115810B1 (pt) composições cosméticas, dermatológicas e farmacêuticas isentas de tensoativos.
NO20065860L (no) Stabiliserte flytende interferonformuleringer
MXPA05008909A (es) Formulacion intranasal de rotigotina.
TW200503754A (en) HSA-free stabilized interferon liquid formulations
ATE354362T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
EA200602137A1 (ru) Гидрогелевые препараты интерферона
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
WO2002085311A3 (en) Hcg formulation
SI1622939T1 (sl) Akrivne variante il-18 vezavnega proteina in medicinske uporabe le-tega
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
ITRM20030363A1 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
IL160190A0 (en) Use of copolymer to produce a galenic form containining a peptide or a protein as active agent
GEP20063821B (en) Orodispersible pharmaceutical composition comprising perindopril
SE0001916D0 (sv) Novel formulation
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
ITRM20020119A0 (it) Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
WO2004111086A3 (fr) ANALOGUES PEPTIDIQUES COMPRENANT AU MOINS UN RESIDU AZA-ß3 AMINOACYLE, ET LEURS UTILISATIONS, NOTAMMENT EN THERAPIE
WO2004032863A3 (en) Oral formulations for proteins and polypeptides
WO2002066513A3 (de) Humane zirkulierende lekti fragmente hf7072, hf7638 und hf14448 sowie ihre verwendung
RU2003124254A (ru) Косметическое средство для ухода за кожей лица и шеи
CY1113593T1 (el) Σκευασματα ανταγωνιστη il-1

Legal Events

Date Code Title Description
FG Grant or registration